Literature DB >> 17212091

[A possibility of overcoming local tumor immune tolerance by radiofrequency ablation in combination with intratumoral injection of naïve dendritic cell].

Hisashi Saji1, Wenru Song, Haruhiko Nakamura, Takamoto Saijo, Makoto Hosaka, Masaru Hagiwara, Akihiko Ogata, Norihito Kawasaki, Edgar G Engleman, Harubumi Kato.   

Abstract

Recently we reported the systemic antitumor efficacy of intratumoral naive dendritic cell injection (IT-DC) in combination with local photodynamic therapy in Clinical Cancer Research 2006. In general, tumor cells secrete several immune suppression cytokines which could induce immune tolerance in a tumor microenvironment. The rationale and advantages of IT DC in combination with conventional antitumor therapy are as follows: (1) dying tumor cells release some tumor antigens, (2) sufficient number of DC recruiting occurs at tumor site, (3) there is naive DC capturing some tumor antigens in vivo, (4) DC activation by inflammatory cytokines are released from dying tumor cells, and (5) DC migration happens in regional lymph nodes and induces adoptive tumor immunity. Conventional antitumor therapy before IT DC could destroy the immune tolerance at a tumor site and induce durable DC vaccination. In this report, we demonstrated the mechanism of (4) and (5) by radiofrequency ablation plus IT DC using mouse tumor model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17212091

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Conductive interstitial thermal therapy (CITT) inhibits recurrence and metastasis in rabbit VX2 carcinoma model.

Authors:  Gal Shafirstein; Yihong Kaufmann; Leah Hennings; Eric Siegel; Robert J Griffin; Petr Novák; Scott Ferguson; Eduardo G Moros
Journal:  Int J Hyperthermia       Date:  2009       Impact factor: 3.914

2.  Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy.

Authors:  Kenichiro Hasumi; Yukimasa Aoki; Ryuko Watanabe; Kim G Hankey; Dean L Mann
Journal:  Cancers (Basel)       Date:  2011-04-28       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.